article thumbnail

Biopharma M&A in 2024 — Five Considerations for Deal Execution

Vantage Partners

Activity among Big Pharmas in 2023 ( Merck + Prometheus ; Pfizer + Seagen ) dominated headlines, and major deal announcements around this year's JPM Healthcare conference (including Merck's acquisition of Harpoon Therapeutics , J&J's acquisition of Ambrx , and GSK's acquisition of Aiolos Bio ) present signals that this trend will only continue (..)

article thumbnail

State of Cloud GTM 2023

Tackle.io

Sits in alliances/partnerships. 2024 PREDICTIONS There has been so much change in the last year around how Marketplace and co-sell are positioned for buyers, for ISVs, and for the Cloud Providers and we expect to see so much more evolution in the coming years. Sits in sales.